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ABSTRACT
Asthma is a complex disorder of inflammation and remodelling largely restricted to the conducting airways. It is
a disorder where there are major genetics and environmental factors that interact together to initiate and propa-
gate the disease into a chronic relapsing disorder. Until recently the genetic factors involved in disease patho-
genesis have been restricted to variants in known molecules involved in the inflammatory or remodelling path-
ways. In this review evidence is presented for a new susceptibility gene for asthma, ADAM 33, that was identi-
fied by positional cloning. It is suggested that ADAM 33 plays a key role in predisposing to reduced lung func-
tion and bronchial hyperresponsiveness characteristic of asthma. Through an understanding of the disease-
related SNPs(in ADAM 33)it may be possible, not only to identify a gene based diagnostic test, but also to fo-
cus attention on developing a new treatment that reverses remodelling changes.
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INTRODUCTION
Asthma is a disorder of the conducting airways in
which the Th-2 mediated inflammation interacts with
structural changes to cause variable airflow obstruc-
tion.1 It is a serious global health problem with over
100 million people affected world wide and the preva-
lence is increasing, especially among children.2,3 Fun-
damental to disordered airway function is the concept
of bronchial hyperresponsiveness(BHR)in which the
airways constrict too much and too easily to a range
of stimuli. In chronic severe asthma, the inflamma-
tion and structural changes both become more in-
tense4 and are paralleled by an increase in BHR that
is only partially or non-responsive to treatment with
corticosteroids.5 Explanations for BHR include mu-
cosal and adventitial swelling causing a disproportion-
ate reduction in airway calibre for a given degree of
airways smooth muscle(ASM)shortening,6 excessive
ASM shortening , 7 increase in ASM mass causing
greater force generation8 and an excessive velocity of
contraction linked to altered cross-bridge cycling . 9
Morphometric studies have shown an increase in
smooth muscle mass in proportion to disease severity
and computer modelling has revealed that this and al-
tered contractility are the most plausible explanations
for BHR.8-10
EARLY LIFE ORIGINS OF ASTHMA
While there is a strong genetic predisposition to-
wards asthma(see below), the increase in prevalence
of the disease that has occurred in the last 30 years2
is too rapid to be accounted for by genetic change in
the population. Rather, it is more likely that it is due
to a shift in environmental influences acting on a pre-
existing genetic susceptibility background. For most
patients with asthma, the disease begins prior to 6
years of age. Beyond this, there is evidence that proc-
esses involved in the development of asthma may be-
gin in utero. Atopy is the major risk factor for the de-
velopment of asthma and it is now well established
that sensitisation may begin in utero.11,12 The poten-
tial for allergic sensitisation and eventual translation
into airways inflammation with wheezing are influ-
enced by many factors in early life, including expo-
sure to tobacco smoke , viral respiratory infections
(particularly respiratory syncytial virus), diet, antibi-
otic use, and domestic(house dust)mite and animal
dander sensitisation at 1 to 2 years of age. The regula-
tion of these processes and resulting balance(or im-
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balance ) in cytokine production is not well estab-
lished, but understanding them is likely to be impor-
tant to the eventual understanding of airway inflam-
mation and the possibility of therapy targeted at in-
juryrepair processes in asthma. Maternal nutrition
may also play a part in lung growth and development.
Subtle deficiencies in vitamin A can affect airway
branching and lung epithelial cell differentiation . 13
There are additional effects on vitamin A depletion on
surfactant protein production, which in turn may in-
fluence airway host defence.14 Other maternal dietary
and environmental factors also influence asthma sus-
ceptibility including the use of medications such as
paracetomol15 and maternal smoking.16 Furthermore,
infants of smoking mothers have been shown to be
much more likely to develop both atopy and wheez-
ing illnesses.17,18
It is well established that both for the early pheno-
types of wheezing in young children, and for later
atopic asthma, airway function and bronchial respon-
siveness measured in the newborn period(and hence
dependant on foetal lung development)are significant
predictors of asthma.19 Recent evidence from an Aus-
tralian cohort has shown that bronchial responsive-
ness in newborns, independent of allergic sensitisa-
tion, is a predictor of the subsequent development of
asthma20 and becomes fully developed by 6 months
of age in high risk infants.21 There may also be an im-
portant interaction between atopy and lung develop-
ment as a recent study has shown between early lung
function(sRaw at age 3 years)and a child’s risk of
atopy.22
These early alterations of lung function result from
the interaction of environmental factors with the de-
veloping lung, which, in genetically susceptible indi-
viduals , leads to structural and downstream func-
tional changes in the airways. This hypothesis is sup-
ported by the recent observation that thickening of
the lamina reticularis in bronchial biopsies from
young children is present several years before
asthma becomes clinically manifest . 23 In addition ,
studies in non-human primates have shown that pre-
natal exposure to nicotine causes collagen deposition
around the large airways . 24 Morphometry has re-
vealed that thickening of asthmatic airways can ac-
count for a large proportion of BHR and excessive air-
way narrowing observed with established disease. In
moderate-severe disease, these structural changes ,
along with BHR, are poorly responsive to corticoster-
oids,25 a finding that was clearly reflected in the EN-
FUMOSA study where evidence of airway wall re-
modelling was found . 26 Of considerable interest is
that changes, including sub-basement membrane col-
lagen deposition, are present in the airways of asth-
matic children27 and may even precede symptomatic
disease.23 This evidence for remodelling may also ac-
count for the lack of effect of inhaled corticosteroids
on post-bronchodilator FEV1 as recently shown in the
longitudinal CAMP and START studies.28,29 The ob-
servation that environmental agents impact on the
bronchial epithelium and that structural remodelling
is associated with tissue injury has led to a study of
these processes with the following conclusions.
1. The susceptibility of the asthmatic bronchial epi-
thelium to oxidant stress is greater than normal, as
reflected by premature apoptosis, and reflects a fun-
damental disease-related difference that has potential
to translate gene-environmental interactions.29
2. In asthma, epithelial repair is prolonged due to
impaired epithelial proliferation caused by an imbal-
ance between proliferation and survival signals.30
3. The altered epithelium communicates with the
underlying mesenchyme to form a trophic unit that
propagates and amplifies remodelling events from
the epithelial surface to the submucosa through acti-
vation of subepithelial effector myofibroblasts.31
4. The epithelial mesenchymal trophic unit
(EMTU)favours localisation of Th-2 mediated inflam-
mation, enabling IL-4 and IL-13 to work in concert
with the EMTU to maintain and amplify the remodel-
ling and inflammatory processes.32
This new concept of asthma helps explain why the
disease is not linearly linked to atopy ; why, not infre-
quently, there is incomplete disease resolution with
corticosteroids ; why in moderate-severe disease in-
haled long acting β-agonists are more effective that
increasing the dose of inhaled corticosteroids and
even then resolution is often incomplete ; and why,
beyond atopy, a range of locally acting environmental
factors(passive tobacco smoke exposure, air pollut-
ants , enzymically active allergens and virus infec-
tions)are important risk factors for the development
and consolidation of this disease．
It follows that Th-2 mediated inflammation and acti-
vation of the EMTU may be parallel rather than se-
quential events with each interacting with the other
and each varying between patients and across time.
In this context, the asthmatic airway could be consid-
ered as a chronic wound where there is injury and
impaired repair and, as a consequence, tissue restruc-
turing and ongoing inflammation. If this is accepted,
then it would seem more appropriate to develop new
therapies that improve epithelial restitution andor
return the EMTU to latency rather than suppressing
inflammation alone．
THE GENETIC BASIS OF ASTHMA
Asthma has a high heritability of up to 75%,33 involv-
ing a few genes with moderate effects rather than
many genes with small effects . 34 Asthma can be
termed a complex genetic disease in that there are
multiple genetic effects that interact with the environ-
ment to modify both susceptibility and severity of dis-
ease.35 Family-based studies of asthma have identi-
fied that in addition to a genetic predisposition to
atopy which alters susceptibility to asthma, there are
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also genetic effects that relate solely to asthma and
possibly regulate susceptibility of the lung to both al-
lergic and other environmental-induced inflamma-
tion. Studies in our own laboratory and those of oth-
ers , have identified candidate regions for asthma
genes based on linkage studies , and also polymor-
phism in candidate genes that are associated with dis-
ease phenotypes.35 While it is clear that asthma re-
sults from the interaction between environmental and
genetic factors, definition has proved difficult due to
the lack of cohorts with extensive environmental ex-
posure data being available for genetic analysis, prob-
lems of defining and quantifying exposure and the
lack of power of most studies . However , a recent
study in a Chinese population which identified an in-
teraction between cigarette smoking and β2-
adrenoceptor genotype in determining susceptibility
to asthma36 indicates the importance of investigating
both genetic and environmental factors in the same
cohort . An observed interaction between a genetic
factor and an environmental factor that leads to in-
creased risk provides support for both observations.
ADAM 33 AS AN ASTHMA SUSCEPTIBILITY
GENE
We have recently reported the first novel asthma- re-
lated gene identified by positional cloning.37 In a five
year collaboration with Genome Therapeutics Corpo-
ration(Waltham, Mass, USA)and Schering Plough
(Kenilworth, NJ, USA), a genome wide screen using
multi-point linkage analysis and 401 microsatellite
markers at a density of 9 cM has been undertaken in-
volving 362 families from Wessex, UK, and 98 from
the USA with a least 2 siblings with asthma . For
doctor-diagnosed asthma , suggestive evidence of
linkage(maximum lod score(MLS)2.24)was found on
chromosome 20 at 9.99 cM. The addition of 13 more
markers at 1―2 cM increased the MLS to 2.94 at
D20S482(12.1 cM)which further increased to 3.93
when BHR was included in the definition of asthma,
thereby exceeding the threshold for genome wide
significance.38 In contrast, when asthma was condi-
tion for serum total IgE and allergen specific IgE, the
MLS fell to 2.3 at 11.6 cM and 1.87 at 12.1 cM respec-
tively, including the presence of genes more closely
linked to airway altered function than to allergic in-
flammation per se. Confirmation of linkage on 20p13
has come from separate analysis of the UK and US
families,37 and from 2 separate genome-wide studies
in other UK and US outbred populations.39,40
Physical mapping and direct cDNA selection identi-
fied 40 genes in the region under the peak of linkage
at 20p13.37 Single-strand conformation polymorphism
(SSCP)analysis and direct sequencing was used to
identify SNPs in association studies involving 130
identical-by-descent affected individuals and 217 hy-
pernormal controls. In 23 genes spanning 1 lod sup-
port interval around D20S482, 105 SNPs were typed
of which 25 localised to a cluster of five genes show-
ing significant association with both asthma and
BHR. Fourteen of these lay within a single gene(No.
216)identified as ADAM 33, a novel member of the
ADAM(A Disintegrin And Metalloprotease ) family
achieving significance of p=0.005―0.05. Both in the
combined populations and the UK and US samples
when analysed separately , additional SNP typing
strengthened the location of the signal to ADAM 33
and this was further confirmed both by haplotype
analysis(5-7 SNP combinations at p=0.000001―0.005)
and transmission disequilibrium ( TDT ) testing ( 10
SNP combinations at P<0.005). Because the alleles on
the ADAM 33 gene that conferred increased risk of
developing asthma and BHR were so common, their
effects translate into a substantial 19―50% population
attributable risk for asthma.37 Replication of the asso-
ciation between ADAM 33 SNPs and asthma has
been seen in studies of both African American, His-
panic and US Caucasian outbred populations41 as well
as two German populations. 42
ADAM 33 EXPRESSION IN ASTHMA
ADAM 33 is the most recently reported member of
the ADAM gene family of Zn+ + - dependant matrix
metalloproteases(MMPs). ADAMs have a complex
organisation involving 8 domains, the first 6 encoding
signal sequence and pro-, catalytic, disintegrin, cyste-
ine rich and EGF domains43 which are anchored at
the cell surface or Golgi apparatus by a transmem-
brane domain followed by a cytoplasmic domain with
signalling specific sequences. ADAM 33 belongs to
the ADAM 12, 15, 19 and 28 subfamily all of which
possess proteolytic activity, e.g. sheddase activity for
HB-EGF(ADAM 12), insulin-like growth factor bind-
ing protein -3 and -5, fibronectin ( ADAM 9 ) , and
TNFα(ADAM 17).43,44 Northern blot analysis identi-
fied two transcripts of ADAM 33 at 5.0 and 3.5 kb, but
only the latter has been found in cytoplasmic RNA.37
17 cDNA libraries have been screened resulting in a
3.5 kb clone containing the entire open reading frame
composed of 22 exons with the canonical splice se-
quence(CTAG)present at each splice junction. The
potential for alternatively spliced transcripts is also in-
dicated by variants lacking exons, or parts of exons.
ADAM 33 is preferentially expressed in smooth mus-
cle, myofibroblasts and fibroblasts, but not in epithe-
lial cells, T-cells or inflammatory leukocytes. In all tis-
sues mRNA transcripts of 5 kb predominated are
those of 3.5 kb by 2-5-fold.45 In Situ hybridisation us-
ing anti-sense ADAM 33 probes has confirmed the
RNA is expressed in smooth muscle, fibroblasts, and
myofibroblasts of asthmatic airways but is not found
in the epithelium , endothelium , or inflammatory
cells.45 The significance of ADAM 33 for asthma is
strengthened by the existence of a synthetic region
on mouse chromosome 2 at 74 cM that has been
linked to BHR46 overlying an orthologue of that ex-
ADAM 33 in Asthma
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hibited ca. 70% homology with its human counterpart.
The selective expression of ADAM 33 in mesen-
chymal cells strongly suggests that alterations in its
activity may underlie abnormalities in the function of
airway smooth muscle cells and fibroblasts linked to
BHR in asthma. These components of the EMTU47
share a common fibroblastic progenitor, the mature
phenotype of which is directed by growth factors in-
cluding TGF-β , 31 whose release from bronchial epi-
thelial cells are increased in response to damage.30-48
Asthmatic(myo)fibroblast cells are unusual in that
they have the capacity to proliferate in the absence of
exogenous growth factors , 31 paralleling the behav-
iour of asthmatic smooth muscle cells in vitro.49 This
shared trait is consistent with the occurrence of a
common stem cell population whose numbers are in-
creased in asthma due to an inherent capacity for en-
hanced cell growth andor survival.
Members of the ADAM family are proteins with di-
verse functions that reflect the complex domain struc-
ture of these molecules.46 While certain functions can
be attributed to an individual domain(e.g. ectodomain
shedding to the metalloproteinase domain50 and cell
adhesion to the disintegrin domain51 ), it is likely that
the other domains play important regulatory roles in
these functions by conferring specificity and selectiv-
ity. ADAM proteins are anchored in the trans -Golgi
network or plasma membrane, but in some cases, se-
creted splice variants have been identified . In the
case of ADAM 12, an evolutionarily close relative of
ADAM 33, ectopic expression of the secreted form of
molecule(ADAM 12S)in rhabdomyosarcoma cells re-
sults in growth of tumour xenografts which are infil-
trated with large numbers of host-derived smooth
muscle cells.52 Although we have identified several al-
ternatively spliced forms of ADAM 33 in lung-derived
cDNA,53 it is not yet known whether a secreted pro-
tein variant is produced by airway cells.
While there is limited published literature sur-
rounding the functions of ADAM 33, we have con-
firmed the selective expression of ADAM 33 mRNA
and protein in fibroblasts, myofibroblasts, and
smooth muscle cells and have further shown that
ADAM 33 occurs in multiple molecular forms that
arise due to alternative mRNA splicing. 53 We have
also found that ADAM 33 expression is rapidly and
transiently upregulated during TGF-β myofibroblasts
differentiation suggesting that it is an early regulator
of differentiation.54
ADAM 33 AND THE EARLY LIFE ORIGINS
OF ASTHMA
ADAM 33 mRNA expression has been shown to oc-
cur during murine embryonic development, suggest-
ing that it regulates tissue morphogenesis.55 In pre-
liminary studies we have found that murine ADAM
33 mRNA expression is induced in embryonic lungs
at the start of branching morphogenesis , increases
with gestation and remains present into adulthood.56
This suggests that polymorphism that modulates
ADAM 33 expression andor function may modulate
lung growth and development in utero and lead to al-
tered airways responsiveness and increased risk of
asthma . In support of the idea that variability in
ADAM 33 may predispose to altered lung function in
early infancy, we have recently shown that ADAM 33
SNPs correlate with lung function measured at age 3
in a cohort of children from Manchester(the MAAS
Study).57 Seventeen single nucleotide polymorphisms
(SNPs)spanning 11Kb of the ADAM 33 gene were an-
alysed in 302 children from a prospective birth cohort
in which respiratory questionnaire and measure-
ments of lung function(sRaw)were completed at age 3
years. We have shown a significant association be-
tween sRaw and 6 SNPs in ADAM 33. In all cases it
was the rare allele that was associated with a higher
sRaw value and therefore, poor lung function. When
compared to children homozygous for the common
allele, carriers of the rare allele had higher sRaw val-
ues for SNPs : V1(p=0.024), Q1(p=0.023), ST+7(p=
0.007)and F+1(p=0.001). The association with F+1
was of interest as there was a clear gene dosage ef-
fect with mean sRaw being 7% higher in heterozygotes
and 12% higher in children homozygous for the rare
allele than in the wild type. Children homozygous for
the rare allele of T1(p=0.001)and T2(p=0.003)also had
significantly higher sRaw values. There was evidence
of linkage disequilibrium between the associated
SNPs suggesting that the effects were not independ-
ent . Using linear regression analysis , we demon-
strated that F+1 was the strongest main effect ; V1, Q
1 and ST+7 had no additional independent effect ,
whereas the effects of T1 and T2 were independent of
F+1. This suggests that there may be more than one
functional polymorphism in the ADAM 33 gene and
that disease-related haplotypes are likely to be mech-
anistically important . These data support the hy-
pothesis that impaired poor early-life lung function is
in part a genetically determined trait involving ADAM
33 that may increase the risk of chronic asthma.
ADAM 33 SNPs AS A PREDICTOR OF SE-
VERE AND PROGRESSIVE ASTHMA
Although the precise role of ADAM 33 in asthma re-
mains unknown, recent epidemiological studies pro-
vide some evidence supporting its role as a suscepti-
bility gene for more severe and progressive disease.
In 200 asthmatics in The Netherlands, in whom longi-
tudinal data on asthma and FEV1 was available over a
20 year period, investigation of 9 SNPs of ADAM 33
when controlled for other variables, e.g. atopy, smok-
ing, showed that two(S2 and Q-1), were significantly
associated with a progressive decline in FEV1 when
compared to normal controls(20.1 vs. 6.4 and 22.1 vs.
4.1 mlyr respectively).58 Mechanistically, this may
be linked to the capacity of TGF-β(and related BMP-
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proteins)to transiently increase ADAM 33 expression
as part of the differentiation trajectory of primitive air-
way mesenchymal cells to myofibroblasts which are
known to be important in chronic wound repair.54
CONCLUDING COMMENTS
Applying genetics to a complex disease such as
asthma is at last realising its potential. In addition to
ADAM 33 novel candidate genes that have been dis-
covered from positional cloning efforts include
PHF11 on chromosome 13q14, the gene product of
which contains two PHD zinc fingers that regulate
transcription involved in IgE synthesis59 and DPP10
on chromosome 2Q14 that encodes a homologue of
dipeptidyl peptidases capable of cleaving terminal
peptides from cytokines and chemokines . 60 How
ADAM 33 and these new genes relate to asthma and
allergy in a functional setting will be a challenge .
However, what is certain, is that the application of
new genetic technologies will reveal further novel
genes involved in the onset and persistence of atopy
and asthma. As well as those genes already described
as interactions of these and others to be discovered
with the environment that will undoubtedly reveal
new ways to prevent and treat this complex disorder.
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